Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00003746|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : May 15, 2012
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if giving cladribine once a day is more effective than giving cladribine once a week in patients with hairy cell leukemia.
PURPOSE: Randomized phase III trial to compare the effectiveness of cladribine given once a day to cladribine given once a week in treating patients with hairy cell leukemia.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Drug: 2-chlorodeoxyadenosine (CDA) daily Drug: 2-chlorodeoxyadenosine weekly||Phase 3|
- Compare the acute hematotoxicity and infection rate with daily and weekly administration of cladribine in patients with hairy cell leukemia.
OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms.
- Arm I: Patients receive daily subcutaneous bolus injections of cladribine (2-CDA) for 5 days (standard dose).
- Arm II: Patients receive weekly subcutaneous bolus injections of 2-CDA for 5 weeks.
Patients showing complete or partial remission at evaluation on day 71 of the first treatment course do not receive any further treatment until relapse or disease progression is evident.
Patients showing minor or no response on day 71 of the first treatment course receive a subsequent course of standard dose 2-CDA.
Patients are followed every 3 months for 2 years, then every 6 months thereafter.
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study within 4 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||100 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||None (Open Label)|
|Official Title:||Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia|
|Study Start Date :||September 1998|
|Actual Primary Completion Date :||November 2005|
|Actual Study Completion Date :||November 2010|
Active Comparator: CDA day
CDA:0.14 mg/kg/day Bolus s.c. (standard) days 1-5
Drug: 2-chlorodeoxyadenosine (CDA) daily
Active Comparator: CDA week
CDA:0.14 mg/kg/week Bolus s.c. weeks 1-5
Drug: 2-chlorodeoxyadenosine weekly
- Acute hematotoxicity at 10 weeks following study treatment [ Time Frame: 10 weeks ]
- Acute infection rate at 10 weeks following study treatment [ Time Frame: 10 weeks ]
- Hospital admission frequency and length at 10 weeks following study treatment [ Time Frame: 10 weeks ]
- Blood support at 10 weeks following study treatment [ Time Frame: 10 weeks ]
- Remission rate [ Time Frame: 10 weeks ]
- Remission duration [ Time Frame: 10 weeks ]
- Relapse-free survival [ Time Frame: 10 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003746
|Bern, Switzerland, CH-3010|
|Study Chair:||Reinhard Zenhaeusern, MD||University Hospital Inselspital, Berne|